Publications by authors named "Gerald G Long"

Claim this Profile
U
Use of Severity Grades to Characterize Histopathologic Changes.
Kenneth A Schafer, John Eighmy, James D Fikes, Wendy G Halpern, Renee R Hukkanen, Gerald G Long

Toxicol Pathol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jacquelin Jolette, Bassem Attalla, Aurore Varela, Gerald G Long, Nacera Mellal

Regul Toxicol Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents.
Richard A Byrd, Steven D Sorden, Thomas Ryan, Thomas Pienkowski, Richard LaRock, Gerald G Long

Endocrinology· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory forum opinion piece: thresholds in toxicologic pathology.
Gerald G Long, Jerry F Hardisty

Toxicol Pathol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic proliferative lesions in the spleen of rasH2 transgenic mice treated with MNU.
Gerald G Long, Dawn G Goodman, Kelly M Credille, Peter C Mann, Jonathan M Wilson

Toxicol Pathol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Commentary on "Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary".
Gerald G Long

Toxicol Pathol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panel discussion: alternative mouse models for carcinogenicity assessment.
John E French, Bernard Leblanc, Gerald G Long, Daniel Morton, Richard Storer

Toxicol Pathol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Gerald G Long, Daniel Morton, Terry Peters, Brian Short, Mikala Skydsgaard

Toxicol Pathol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.
Gerald G Long, Vincent L Reynolds, L Wayne Dochterman, Thomas E Ryan

Toxicol Pathol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
Gerald G Long, Vincent L Reynolds, Alric Lopez-Martinez, Thomas E Ryan, Sandy L White

Toxicol Pathol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variations in animal populations over time and differences in diagnostic thresholds used can impact tumor incidence data.
John L Vahle, Masahiko Sato, Gerald G Long

Toxicol Pathol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
John L Vahle, Gerald G Long, George Sandusky, Michael Westmore, Yanfei Linda Ma

Toxicol Pathol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apparent mesonephric duct (rete anlage) origin for cysts and proliferative epithelial lesions in the mouse ovary.
Gerald G Long

Toxicol Pathol· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
John L Vahle, Masahiko Sato, Gerald G Long, Jamie K Young, Paul C Francis

Toxicol Pathol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis